Goldman Sachs’s Rein Therapeutics RNTX Stock Holding History

Goldman Sachs’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83K	Buy	+79,785	New	+$96.5K	﹤0.01%	6358
2021 Q1	–	Sell	-1,660	Closed	-$35K	–	6404
2020 Q4	$35K	Buy	+1,660	New	+$41.5K	﹤0.01%	5412
2020 Q3	–	Sell	-1,249	Closed	-$29K	–	5570
2020 Q2	$29K	Buy	+1,249	New	+$20.4K	﹤0.01%	5109
2018 Q3	–	Sell	-597	Closed	-$65K	–	5828
2018 Q2	$65K	Buy	+597	New	+$67.6K	﹤0.01%	5297
2017 Q3	–	Sell	-1,875	Closed	-$418K	–	6901
2017 Q2	$418K	Buy	+1,875	New	+$412K	﹤0.01%	5239

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Goldman Sachs's RNTX Position: Q2 2026 in Review

Goldman Sachs opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 79,785 shares worth $83K. The stake represents ﹤0.01% of the portfolio and ranks #6358 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in RNTX as recently as Q4 2020.

Goldman Sachs first reported a position in RNTX in Q2 2017 and has held it in 5 quarters since. The position peaked at $418K in Q2 2017. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Goldman Sachs held 79,785 shares of Rein Therapeutics worth $83K as of Q2 2026.
Rein Therapeutics was a new Goldman Sachs position in Q2 2026.
Rein Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6358 holding.
Goldman Sachs first reported a position in Rein Therapeutics in Q2 2017 and has held it in 5 quarters since.
Goldman Sachs's Rein Therapeutics position peaked at $418K in Q2 2017.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.